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Abstract
Background: An implantable cardioverter-defibrillator (ICD) is routinely used to prevent 
sudden cardiac death. Since the introduction of that device into clinical practice, a defibril-
lation test (the so-called pre-discharge test [PDT]) has been an inseparable part of the ICD 
implantation procedure. Recently, the usefulness of PDT has been called into question.
Methods: The aim of this research was to analyze ICD tests performed within two time peri-
ods: in years 1995–2001 (period I) and 2007–2010 (period II), in order to compare the results 
of tests and solutions to all the problems with ICD systems revealed by means of PDT.
Results: During period I, 193 tests were performed, among which the ICD system malfunction 
was observed in 16 cases. Those included: sensing issues, specifically R-wave undersensing 
during ventricular fibrillation (VF) (7 patients) and T-wave oversensing (4 patients), as well as 
high defibrillation threshold (DFT) (2 patients) and ICD-pacemaker interaction (3 patients). 
During period II, among 561 tests, system malfunction was observed in 15 cases. In 1 patient 
it was VF undersensing, and in the remaining 14 it was high DFT. All the above problems were 
solved by means of appropriate ICD reprogramming, repositioning of the endocardial defibril-
lation lead or implantation of an additional subcutaneous defibrillation lead.
Conclusions: Contemporary ICD technical solutions, compared to older systems, in most 
cases allow to avoid sensing problems. The key rationale behind ICD testing is the ability to 
confirm the efficacy of high-voltage therapy. Despite the increasing maximal defibrillation out-
put of devices, and all possible adjustments to the characteristics of the impulse, there is still 
a group of patients that require additional procedures to ensure the appropriate defibrillation 
efficacy. (Cardiol J 2016; 23, 5: 532–538)
Key words: pre-discharge test, PDT, implantable cardioverter-defibrillator, ICD
Introduction
An implantable cardioverter-defibrillator (ICD) 
is commonly used to prevent sudden cardiac death 
(SCD) due to ventricular arrhythmias. Since the 
introduction of that device into clinical practice, 
a defibrillation test (so-called pre-discharge test 
[PDT]) has been an inseparable part of the ICD 
implantation procedure. PDT used to be performed 
during ICD implantation procedure or immediately 
after the procedure, but increasingly often it takes 
place several days after implantation. It is based 
on the induction of ventricular fibrillation (VF), 
which is then detected and terminated by an ICD 
shock, which depends on the protocol of the test 
and the ICD model. The main aim of the test is to 
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confirm the appropriate arrhythmia detection, as 
well as the efficacy of the defibrillation impulse (the 
energy of which usually equals the maximum ICD 
output less 10 J). PDT also proves the integrity 
of the ICD-lead(s) system and its connections, 
allows to assess the sensing/detection and pacing 
settings, and to develop the final program of the 
device. Sometimes, the PDT is used to establish 
the lowest energy that terminates VF, the so-called 
defibrillation threshold (DFT).
In recent years, some authors have called into 
question the usefulness of routine PDT. The key 
argument is that most information resulting from 
PDT can be acquired by other means. Moreover, 
execution of PDT does not influence mortality of 
ICD recipients, which in the light of the risk of 
PDT itself puts the usefulness of that procedure 
in question [1, 2]. On the other hand, one might 
argue that in some patients, the result of PDT 
brings useful information and influences further 
clinical approach. Moreover, in recent years, we 
have observed considerable progress in cardiac 
electrotherapy and there is clearly a need to com-
pare former PDT results with those of today in 
terms of their clinical significance.
The aim of the study was to compare the re-
sults of ICD testing and the following strategy to 
solve all the clinical problems revealed during the 
tests. We investigated the change in PDT results 
over 15 years of ICD use in our department and in 
the management strategy of ICD-recipients. For 
that purpose, we retrospectively analyzed the data 
of patients that have undergone ICD implantation 
in our department in two time periods: in years 
1995–2001 and 2007–2010 (Table 1).
Methods
Group A was selected from 228 consecutive 
patients that underwent an ICD implantation pro-
cedure in years 1995–2001 (period I). Thirty-five 
patients were excluded from that group due to lack 
of Holter memory in the implanted device, which 
would allow to record intracardiac electrograms 
(Phylax 03, Biotronik), or due to incomplete medi-
cal history. As a result, 193 patients (52 female, 
141 male) at the age of 18–80 (mean 55.8 ± 15.3), 
who had a PDT performed after the implantation 
procedure, turned out to be eligible for further 
analysis. In that group, the system malfunction was 
discovered during the PDT in 16 patients (group A). 
That group consisted of 5 women and 11 men who 
were 30–80 years of age (mean 55 ± 14.4). The 
primary underlying condition was coronary artery 
disease (CAD) in 13 patients, dilative cardiomyopa-
thy (DCM) in 2 patients, and long QT syndrome in 
1 patient. Three patients had an additional pace-
maker implanted (1 — AAI, 1 — DDD, 1 — VVI). 
Left ventricular ejection fraction (LVEF) was 
20–70% (mean 42.1 ± 16.9). All patients had un-
dergone sudden cardiac arrest and were qualified 
for an ICD in secondary prevention of SCD. All the 
devices but one were single-chamber, manufac-
tured by Biotronik: Phylax 06 — 6 patients, Phylax 
XM — 4 patients, Mycrophylax — 5 patients. One 
patient received a dual-chamber ICD — Phylax AV, 
also manufactured by Biotronik.
Group B was selected from 610 consecutive 
patients that underwent ICD implantation proce-
dure in years 2007–2010 (period II). In that group, 
a PDT was conducted in 561 patients (131 female, 
430 male), at the age of 18–92 (mean 61.6 ± 13.1). 
PDT was not performed in 49 patients due to typi-
cal contraindications (persistent atrial fibrillation 
or artificial valve prosthesis without appropriate 
anticoagulation, cardiac chamber thrombus, hemo-
dynamic instability, significant aortic stenosis, 
prior stroke, symptomatic CAD, CAD not eligible 
for revascularization). In 5 cases, VF could not be 
induced during PDT, despite repeated attempts and 
various induction protocols. The system malfunc-
tion was revealed during PDT in 15 patients and 
Table 1. Implantable cardioverter-defibrillator (ICD) implantation procedures and ICD tests in both  
analyzed periods.
Period I  
(years 1995–2001)
Period II  
(years 2007–2010)
P
Total number of ICD implantation procedures 228 610 –
Total number of ICD tests 228 561 –
Number of tests included in the analysis 193 556 –
Number of tests without ventricular fibrillation induction 0 (0%) 5 (0.9%) NS
Number of tests that revealed system malfunction 16 (8.3%): group A 15 (2.7%): group B < 0.001
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that group constituted a subject for further analysis 
(group B). It consisted of 2 women and 13 men, at 
the age of 32–68 (mean 51.2 ± 10.3). The under-
lying condition was CAD in 7 patients, DCM in 
6 patients, and laminopathy in 1 patient. LVEF 
range was 15–65% (mean 28.3 ± 13.5). In 6 pa-
tients, the ICD had been implanted in the second-
ary prevention, and in 9 patients, in the primary 
prevention of SCD. The devices were as follows: 
single-chamber in 5 patients, dual-chamber in 5, 
and bi-ventricular in 5 patients. The devices were 
manufactured by Biotronik (Lumos DR — 1, Lu-
max 340 VR — 1, Lumax 340 DR — 1), Medtronic 
(Insync Sentry — 3, Insync Maximo — 1, Maximo 
VR — 4, Maximo DR — 1, Maximo II DR — 1, 
Maximo II CRT — 1) and Boston Scientific (Teligen 
100 DR — 1).
Pre-discharge tests were performed in an 
electrophysiology laboratory, 1–30 days after the 
ICD implantation procedure. Following the thor-
ough sensing and pacing parameters control, VF 
was induced under short-term general anesthesia, 
instituted by an anesthesiologist. Shock-on-T or 
burst pacing were used as VF induction methods. 
The PDT protocol was different in both of the 
analyzed periods. In years 1995–2001, the test 
consisted of repeated VF induction and defibrilla-
tion with an adjusted energy, aimed at determining 
the DFT (the lowest energy sufficient to terminate 
the arrhythmia and restore the sinus rhythm). The 
first energy value tested was 13 J. Subsequently, 
8 J, 4.5 J, and 3.1 J values were tested. If the first 
13 J value, shock was inefficient, the energy value 
of 21 J was tested, and if that in turn was effective, 
the 18 J shock followed. The PDT result was sat-
isfactory if VF was terminated twice with a shock 
of no more than 21 J. In years 2007–2010, a single 
defibrillation efficacy test was used, without deter-
mination of the DFT. For the time of the test, the 
ICD was programmed to deliver the first shock of 
maximum energy of a particular device of less 10 J 
(max –10 J) or less 15 J (max –15 J). The second 
shock was the maximum energy of the device in 
the former case, and the maximum energy less 10 J 
in the latter case. All the following shocks were 
of the maximum available output. The test was 
deemed satisfactory if VF was terminated by the 
shock max –10 J or max –15 J. During both analyzed 
periods, if the test was unsatisfactory (period I: 
DFT > 21 J, period II: DFT > max –10 J) the test was 
repeated with reversed shock polarity. In group A, 
5 out of 16 patients had a dual-coil lead, while in 
group B it was 1 out of 15 patients. The shock 
configuration was initially set as default setting of 
every ICD. In dual-coil systems, it was always dis-
tal shocking electrode (HVB) to the proximal elec-
trode (SVC) and to the pulse generator case (can). 
If the measures described above were insufficient 
to achieve the pre-set defibrillation safety margin, 
the patient was qualified for the defibrillation lead 
repositioning (period I) or the implantation of 
a subcutaneous defibrillation lead (period II).
Our study had completely retrospective char-
acter based on medical history analysis no personal 
data of the patients was used and due to this the 
bioethical committee opinion was not needed.
Statistical analysis
All statistical analyses were performed with 
the use of Statistica 10 PL, StatSoft. Descriptive 
statistics used numbers and percentages, mean 
value and standard deviation, and the maximum and 
minimum values. Normal distribution of continu-
ous variables was assessed with the Shapiro-Wilk 
W test. Variance homogeneity was tested with the 
Levene’s test. Variables with normal distribution 
and homogenous variances were compared using 
the Student’s t-test for unrelated variables. If 
variances were not homogenous, the Cochrane-
Cox test was used. If normal distribution could 
not be confirmed, variables were compared with 
the Mann-Whitney U test. In all the analyses, the 
border confidence value for rejection of the null 
hypothesis was set as a = 0.05. The calculated 
p-value for each test, if lower than 0.05, was labeled 
adequately as: p £ 0.05, p £ 0.01, and p £ 0.001.
Results
During period I, the system malfunction was 
observed in 16 cases among 193 ICD tests (group A). 
The problems were: detection disorders — 
R wave undersensing during VF (7 patients), T-wave 
oversensing (4 patients), high DFT (2 patients) 
and ICD-pacemaker interactions — oversensing of 
atrial pacing impulse of the AAI pacemaker in the 
ventricular channel of the ICD (1 patient), over-
sensing of ventricular pacing impulse of the DDD 
pacemaker in the ventricular channel of the ICD 
(1 patient) and undersensing of VF due to unin-
hibited ventricular pacing of the VVI pacemaker 
during VF (1 patient). During period II, system 
malfunction was observed in 15 cases among 561 
ICD tests. In 1 case, it was undersensing of VF, and 
in the remaining 14 cases — high DFT (group B). 
These data are presented in Table 2. Numbers of 
patients in both groups and tests and system mal-
functions are summarized in Figure 1.
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Troubleshooting of problems  
revealed during PDT
In case of R-wave undersensing in group A, 
the following program changes were introduced: 
an increase of the ICD ventricular sensitivity 
(6 patients), reduction of the number of intervals 
for VF detection (“X of Y criterion” — 3 patients), 
turning off the confirmation of detection before 
shock (“confirmation OFF” — 2 patients), repro-
gramming of the VF detection window to the lower 
value (2 patients), and inversion of the ventricular 
intracardiac signal (3 patients). In all patients with 
T-wave oversensing, the filtration settings of in-
tracardiac electrogram were changed. In order to 
exclude the ICD-pacemaker interactions, the pac-
ing impulse configuration was changed to bipolar, 
with the lowest possible output value, and with 
the maximum sensing setting of the pacemaker. In 
case of high DFT, the polarity of the defibrillation 
impulse was reversed. One patient required double 
repositioning of the defibrillation lead.
The repeated ICD test after having introduced 
the above measures, proved their efficacy — no 
detection problems were observed, and successful 
defibrillation was achieved with the energy value 
of £ 21 J.
In group B, in case of VF undersensing, the 
device sensitivity was increased (1 patient). In case 
of high DFT, the reversed polarity impulse was 
tested. It was satisfactory in 4 patients, and the 
remaining 10 patients required the implantation 
of an additional subcutaneous defibrillation lead.
Discussion
At the end of the last century, some authors 
already advised abandoning the routine of ICD test-
ing [3, 4]. The usefulness of PDT is questioned also 
Figure 1. Diagram summarizing numbers of patients, tests and system malfunctions in both study groups;  
PDT — pre-discharge test; SCD — sudden cardiac death; VF — ventricular fibrillation.
Table 2. Detailed data of patients in groups A and B, and system malfunctions during implantable  
cardioverter-defibrillator (ICD) tests in both groups.
Group A Group B P
Number of patients 16 15
Number of M/F (percentage of M/F) 11/5 (69%/31%) 13/2 (87%/13%) < 0.001
Age 30–80 (mean 55 ± 14.4) 32–68 (mean 51.2 ± 10.3) NS
Left ventricular ejection fraction 20–70% (mean 42.1 ± 16.9) 15–65% (mean 28.3 ± 13.5) NS
Undersensing of VF 7/193 = 3.6% 1/561 = 0.2% < 0.001
T-wave oversensing 4/193 = 2.1% 0/561 = 0% < 0.001
PM-ICD interactions 3/193 = 1.6% 0/561 = 0% < 0.001
High defibrillation threshold 2/193 = 1% 15/561 = 2.7% NS
F — female; M — male; PM — pacemaker; VF — ventricular fibrillation
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contemporarily [5–7]. According to some experts, 
most of the essential information can be acquired 
during normal follow-up of the device. That in-
cludes confirmation of appropriate sensing with 
the sensing test, or the proof of correct ICD-lead 
connection by the means of electrical impedance 
measurements. There is also some doubt about the 
efficacy of a defibrillation test, which is the most 
crucial part of PDT. According to some experts, 
successful defibrillation has low repeatability, as 
it is influenced both by numerous clinical (drugs, 
hypoxia, anemia, acidosis, electrolyte imbalance, 
increase of the left ventricular wall thickness) and 
physical conditions (concerning the characteristics 
of a defibrillation impulse itself). Moreover, the 
controversy is augmented by the variety of PDT 
protocols and lack of guidelines for proper inter-
pretation of test results. The question still remains 
unanswered, whether the arrhythmia induced dur-
ing PDT is clinically relevant, and whether it is 
reasonable to test responses to VF, as most real-life 
episodes recorded by ICDs are ventricular tachy-
cardias. An important argument against PDT is the 
risk of general anesthesia and VF induction. Finally, 
it should be emphasized that data from clinical tri-
als did not show a significant mortality reduction 
that could be expected for PDT and the additional 
confirmation of ICD system integrity and function 
[8, 9]. The results of the SIMPLE trial which did 
not show any benefit of performing a PDT, seem 
to be important in that matter [10]. Importantly, 
retrospective observations, however, are still of 
interest for clinicians, as they show results based 
on real-life subsets of all consecutive patients [11]. 
Thus, in our opinion, despite all doubts, ICD tests 
should be routinely used, as in some patients, the 
PDT result significantly influences the further 
clinical approach. This includes the modification of 
sensing parameters in case of sensing issues during 
PDT, as well as the change of shock characteristics, 
the implantation of a subcutaneous defibrillation 
lead, or device replacement for a higher-energy 
model in case of high DFT.
The aim of this study was to assess, whether 
the results of PDT during 15 years of ICD use in 
our department justify the decision to abandon the 
routine of ICD testing. Our data show that cur-
rent ICDs have sensing and detection algorithms 
superior to older ones. Appropriate programma-
ble filters, in most cases pre-determined with no 
further detailed modification options, as well as 
digital processing of the intracardiac electrogram, 
almost entirely eliminate sensing and detection 
issues. Such system malfunction was observed in 
11 (5.7%) cases during period I and merely in 1 (0.2%) 
case during period II (p < 0.001). It was mainly 
VF undersensing in older ICD models in 7 (3.6%) 
cases. That result is comparable to other reports 
from that era [3, 12, 13]. During period II, under-
sensing was observed only in 1 case. Also, the 
T-wave oversensing (4 cases in years 1995–2001) 
was almost entirely eliminated (no such case in 
years 2007–2010) (p < 0.001). The introduction of 
dual-chamber and bi-ventricular ICDs eliminated 
the problem of ICD-pacemaker interactions in 
patients that require both permanent pacing and 
an ICD. In the cases described in the article, AAI 
and DDD pacemakers were left due to the need for 
atrial pacing and the lack of that possibility in the 
ICD systems that were available at that time in our 
country. The VVI pacemaker was left to prevent 
ICD battery use for ventricular pacing, especially if 
the PM system was implanted long before the ICD, 
and the lack of technical ability to extract leads at 
that time. Obviously,, in the modern era, this notion 
is never used again, but to our knowledge, in the 
pioneering ICD era, the co-existence of ICD and 
pacemakers was not that rare.
What is of great significance, the high DFT 
still remains an issue. In our cohort of patients 
with modern ICD systems, during period II, it was 
observed even in a higher percentage, although 
this difference did not reach statistical significance. 
That result is close or slightly lower than reported 
by other authors. Osswald et al. [14] observed 
high defibrillation threshold in 6.3% of patients. 
Verma et al. [15] defined high defibrillation thresh-
old as an unsuccessful 25 J shock, observed that 
phenomenon in 5.1% of patients, and implanted 
subcutaneous leads in all such patients with final 
success. Brigniole et al. [6] did not achieve a 10 J 
safety margin in 7% of patients in their group, and 
in 3.6% of patients even the shock with maximal 
output energy was not efficient. It may result from 
the fact that in our report, the high DFT was de-
fined as DFT of more than 21 J (period I) or more 
than the maximum energy output of the device less 
10 J (period II). As various ICD models were used, 
in some patients in group B, high DFT means the 
DFT value of > 25 J, and in some of > 30 J. In the 
literature, high DFT was defined as the value of 
> 18 J, especially in the era when the maximum 
output was not higher than 30 J. Because of that, 
the incidence of high DFT in particular publications 
may vary. In the most recent SIMPLE study cohort, 
in the group that was subject to defibrillation test-
ing, the high DFT (above 21 J) was observed in 
99 of 1,218 patients (which is 8.1%). In our study, 
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the greater incidence of high DFT in group B may 
have several explanations: in group A, 5 out of 
16 patients had a dual-coil lead, while in group B, it 
was 1 out of 15 patients. The LVEF value tended 
to be lower in group B (although it was not statisti-
cally significant). During period II, more patients 
had biventricular devices. And, in older times, 
patients were more often implanted in second-
ary prevention (with primary VF in otherwise 
organically healthy hearts), while contemporarily 
the tendency is to implant ICDs in primary pre-
vention of SCD. All of the abovementioned factors 
may have led to the divergent percentage of high 
DFT. It is important to underline that during both 
periods of time taken into our analysis, the scheme 
of defibrillation testing was different (multiple 
inductions in period I, as limited induction as 
possible in period II). It is a result of different 
routine of defibrillation testing in those periods, 
which changed in time with emerging scientific 
evidence. It cannot be excluded that different 
protocols might have led to divergent results, and 
that is one of possible limitations of our analysis, 
however major problems revealed during the test 
during the period I were associated with sensing 
and pacemaker-ICD interactions, which were not 
dependent on the actual number of inductions and 
subsequent defibrillation setting.
The problem of high DFT justifies the use of 
PDT. It would be inappropriate to avoid ensuring 
patients that the device intended to save their lives 
works properly right away from the implantation 
procedure. Can one ignore the unsuccessful test 
defibrillation performed in clinically controlled con-
ditions, in a stable patient, that has been carefully 
prepared for the test? Can one expect the efficacy 
of such a device during the follow-up, in case of 
spontaneous arrhythmia, that is likely to occur dur-
ing circulatory decompensation or ischemia, which 
further decrease the likelihood of the arrhythmia 
termination? It seems that the ICD system that 
acutely fails to perform its intended role requires 
modification or replacement. That condition can 
only be confirmed with PDT. Recently, even more 
doubt about the value of defibrillation testing has 
been raised by the results of the SIMPLE trial, in 
which the no-testing turned out to be non-inferior 
to the testing strategy in terms of a combined 
endpoint of arrhythmic death or unsuccessful first 
shock [10]. In our opinion however, and to what we 
understand from the results of that trial, it is impor-
tant to underline that in the group randomized to 
ICD testing, 99 out of 1,218 patients had eventually 
an unsuccessful test, despite all the undertaken 
measures, which are unfortunately not discussed 
in great detail. The real value of PDT depends on 
its ability to identify patients with unsatisfactory 
safety margin of defibrillation energy, but it only 
makes sense if we react in a way that allows to 
achieve finally the efficacy as close to 100% as 
possible, that is, for example, placement of an ad-
ditional subcutaneous lead or changing the device 
for a higher-voltage model.
At the same time, one should appreciate the 
fact that a successful PDT does not guarantee 
the 100% efficacy of the system in the future. 
The energy levels required to terminate VF may 
vary depending on the clinical situation. That fact 
might explain the occurrence of SCD in a certain 
percentage of ICD recipients [16, 17]. Therefore, it 
is crucial to identify the group of patients, in whom 
a PDT is particularly needed, because of the high 
risk of system malfunction. Our data show that 
contemporarily “system malfunction” means in 
most cases the high DFT. We did not analyze our 
cohort in the search of risk factors for high DFT, 
but those were previously identified in other pub-
lications [11]. In conclusion, it may be reasonable 
to limit the PDT to the group of patients at risk 
of high DFT.
Conclusions
Contemporary technical solutions used in 
ICD systems, compared to previous years, allow 
to avoid most sensing disorders and ensure appro-
priate VF detection. The reason that justifies ICD 
defibrillation testing is the need to confirm the ef-
ficacy of high-voltage therapy. Despite increasingly 
high-energy values of the defibrillation impulse and 
available adjustments of its characteristics, there 
is still a group of patients who require additional 
procedures to achieve the appropriate defibrilla-
tion safety margin. That condition may be identi-
fied only by means of a pre-discharge test of the 
implanted ICD system.
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